AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
Deciding between established drugmakers requires balancing current income with future growth. You might be weighing AbbVie Inc. (NYSE:ABBV) against Novo Nordisk A/S (NYSE:NVO) to see which healthcare giant fits best in 2026.
AbbVie is evolving beyond its historic reliance on a single blockbuster treatment by investing heavily in immunology and oncology. Meanwhile, Novo Nordisk focuses on metabolic health, benefiting from a massive surge in demand for its obesity medications. Both companies operate in the competitive pharmaceutical sector but offer very different risk and reward profiles.
AbbVie is a global biopharmaceutical player focused on developing advanced therapies for complex health issues. It competes among pharmaceutical stocks by focusing on high-impact treatments in immunology, oncology, and neuroscience. In its latest annual report, filed for the year 2025, the company highlighted a commercial strategy targeting physicians and government payers. Its U.S. distribution depends on three major wholesalers: McKesson Corp. (NYSE:MCK), Cardinal Health (NYSE:CAH), and Cencora (NYSE:COR). These three partners account for nearly all of its domestic pharmaceutical sales. Customer concentration like this adds a layer of risk to the business. The company also manages a growing aesthetics portfolio through direct-to-physician sales.
Source: www.fool.com — article syndicated from the publisher’s feed; all rights remain with the original publisher.